BPG is committed to discovery and dissemination of knowledge
Retrospective Study
Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Nov 15, 2026; 18(11): 123385
Published online Nov 15, 2026. doi: 10.4251/wjgo.123385
Table 4 Univariate and multivariate Cox analysis for progression-free survival
CharacteristicsUnivariate analysis
Multivariate analysis
HR (95%CI)

P value
HR (95%CI)

P value
Gender (female vs male)1.552 (0.939-2.566)0.0871.800 (0.891, 3.635)0.101
Age (< 65 vs ≥ 65 years)0.909 (0.606-1.364)0.645
Hepatitis B infection (no vs yes)1.246 (0.793-1.957)0.340
Hepatitis C infection (no vs yes)0.923 (0.128-6.635)0.936
Diabetes (no vs yes)1.484 (0.794-2.772)0.216
Hypertension (no vs yes)0.927 (0.627-1.372)0.707
Smoking (no vs yes)0.748 (0.501-1.117)0.156
Drinking (no vs yes)0.762 (0.488-1.192)0.234
Tumor size (≤ 5 vs > 5 cm)1.021 (0.618-1.688)0.935
Child-Pugh class (A vs B + C)1.680 (0.995-2.837)0.0521.260 (0.658-2.414)0.485
ECOG PS (0 vs ≥ 1)1.171 (0.662-2.072)0.587
Portal vein invasion tumor (no vs yes)1.210 (0.762-1.919)0.419
CNLC (IIa + IIb vs IIIa + IIIb)1.139 (0.787-1.649)0.490
ALT (≤ 50 vs > 50 IU/L)1.037 (0.689-1.560)0.863
AST (≤ 40 vs > 40 IU/L)1.233 (0.840-1.810)0.284
ALB (< 35 vs ≥ 35 g/L)0.692 (0.466-1.027)0.0680.698 (0.425-1.176)0.177
TBIL (≤ 23 vs > 23 μmol/L)0.982 (0.641-1.505)0.934
AFP (< 400 vs ≥ 400 ng/mL)1.908 (1.285-2.834)0.0011.749 (1.027-2.980)0.040
INR (≤ 1.2 vs > 1.2)0.878 (0.380-2.026)0.760
First-line ICI therapy (no vs yes)1.344 (0.915-1.974)0.132
Initial daily dose of regorafenib (< 160 vs 160 mg)1.020 (0.593-1.755)0.942
Second-line PD-1 therapy (no vs yes)0.561 (0.379-0.830)0.0040.549 (0.31-0.953)0.033


Write to the Help Desk